{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:54:21Z","timestamp":1785596061781,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05676-1","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T01:01:40Z","timestamp":1708909300000},"page":"3179-3191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS"],"prefix":"10.1007","volume":"103","author":[{"given":"Muhammed Favas","family":"KT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Semwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beema T","family":"Yoosuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4520-3293","authenticated-orcid":false,"given":"Dipika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"5676_CR1","doi-asserted-by":"crossref","unstructured":"Hardwick JM, Soane L (2013) Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol. 5(2)","DOI":"10.1101\/cshperspect.a008722"},{"issue":"18","key":"5676_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40265-020-01433-6","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair HA, Venetoclax (2020) A review in previously untreated chronic lymphocytic leukaemia. Drugs 80(18):1973\u20131980","journal-title":"Drugs"},{"key":"5676_CR3","doi-asserted-by":"publisher","first-page":"204062072098664","DOI":"10.1177\/2040620720986646","volume":"12","author":"I Aldoss","year":"2021","unstructured":"Aldoss I, Pullarkat V, Stein AS (2021) Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol 12:2040620720986646","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"5676_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","volume":"61","author":"C Lachowiez","year":"2020","unstructured":"Lachowiez C, DiNardo CD, Konopleva M (2020) Venetoclax in acute myeloid leukemia - current and future directions. Leuk Lymphoma 61(6):1313\u20131322","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"5676_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S et al (2018) Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107\u20131120","journal-title":"N Engl J Med"},{"key":"5676_CR6","unstructured":"Food US, Administration D FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy. 2018 [cited 2023 July 19] 2018 [Available from: https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm610308.htm"},{"key":"5676_CR7","unstructured":"FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia (2020). [cited 2023 July 19] 2020 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia"},{"issue":"11","key":"5676_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"5676_CR9","doi-asserted-by":"crossref","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JA Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions2019. p. 205\u2009\u2013\u200928","DOI":"10.1002\/9781119536604.ch8"},{"issue":"2","key":"5676_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","volume":"14","author":"M Borenstein","year":"2013","unstructured":"Borenstein M, Higgins JP (2013) Meta-analysis and subgroups. Prev Sci 14(2):134\u2013143","journal-title":"Prev Sci"},{"issue":"7414","key":"5676_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"20","key":"5676_CR12","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25(20):3443\u20133457","journal-title":"Stat Med"},{"issue":"7109","key":"5676_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"6","key":"5676_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"5676_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"key":"5676_CR16","doi-asserted-by":"crossref","unstructured":"Wang W, Luo Q, Chen Q, Pang A, Fang K (2022) Analysis of the Clinical Efficacy of Azacytidine\u2009+\u2009Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia. Evidence-Based Complementary and Alternative Medicine. 2022","DOI":"10.1155\/2022\/8691835"},{"issue":"1","key":"5676_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","volume":"52","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T et al (2022) Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol 52(1):29\u201338","journal-title":"Jpn J Clin Oncol"},{"issue":"24","key":"5676_CR18","first-page":"2137","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood J Am Soc Hematol 135(24):2137\u20132145","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"5676_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A-M, Robrecht S et al (2020) Venetoclax plus Obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 21(9):1188\u20131200","journal-title":"Lancet Oncol"},{"issue":"12","key":"5676_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S et al (2018) Venetoclax\u2013Rituximab in relapsed or refractory chroni lymphocytic leukemia. N Engl J Med 378(12):1107\u20131120","journal-title":"N Engl J Med"},{"key":"5676_CR21","unstructured":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)\/\u200bSmall Lymphocytic Lymphoma (SLL) (GLOW) ClinicalTrials.gov: National Library of medicine; [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03462719"},{"issue":"1","key":"5676_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/16078454.2020.1843752","volume":"25","author":"B Liu","year":"2020","unstructured":"Liu B, Guo Y, Deng L, Qiao Y, Jian J (2020) The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Hematology 25(1):414\u2013423","journal-title":"Hematology"},{"issue":"2","key":"5676_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10238-021-00784-y","volume":"23","author":"Y Qin","year":"2023","unstructured":"Qin Y, Kuang P, Liu T (2023) Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis. Clin Exp Med 23(2):219\u2013227","journal-title":"Clin Exp Med"},{"issue":"4","key":"5676_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al (2016) Targeting BCL2 with Venetoclax in Relapsed Chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"2","key":"5676_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS et al (2017) Venetoclax plus Rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 18(2):230\u2013240","journal-title":"Lancet Oncol"},{"issue":"4","key":"5676_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clml.2020.10.012","volume":"21","author":"S Molica","year":"2021","unstructured":"Molica S, Giannarelli D, Montserrat E (2021) Comparison between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic lymphocytic leukemia (CLL): a systematic review and network Meta-analysis. Clin Lymphoma Myeloma Leuk 21(4):216\u2013223","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5676_CR27","doi-asserted-by":"crossref","unstructured":"Kim H-S, Lee S, Kim JH (2018) Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 33(34)","DOI":"10.3346\/jkms.2018.33.e213"},{"issue":"7","key":"5676_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10(7):796","journal-title":"Int J Med Sci"},{"issue":"12","key":"5676_CR29","doi-asserted-by":"publisher","first-page":"e0278725","DOI":"10.1371\/journal.pone.0278725","volume":"17","author":"Y Yang","year":"2022","unstructured":"Yang Y, Shu Y, Chen G, Yin Y, Li F, Li J (2022) A real-world pharmacovigilance study of FDA adverse event reporting System (FAERS) events for venetoclax. PLoS ONE 17(12):e0278725","journal-title":"PLoS ONE"},{"key":"5676_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijcard.2021.10.011","volume":"344","author":"US Grewal","year":"2021","unstructured":"Grewal US, Thotamgari SR, Sheth AR, Gaddam SJ, Ahmad J, Beedupalli K et al (2021) Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: a pharmacovigilance analysis. Int J Cardiol 344:186\u2013189","journal-title":"Int J Cardiol"},{"key":"5676_CR31","unstructured":"National Comprehensive Cancer Network (2021) NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V1.2022. [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"issue":"279","key":"5676_CR32","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al (2015) Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 7(279):279ra40","journal-title":"Sci Transl Med"},{"issue":"1","key":"5676_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11899-017-0359-0","volume":"12","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Davids MS (2017) The Development and current use of BCL-2 inhibitors for the treatment of chronic lymphocytic leukemia. Curr Hematol Malig Rep 12(1):11\u201319","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"5676_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17(6):768\u2013778","journal-title":"Lancet Oncol"},{"issue":"15","key":"5676_CR35","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","volume":"131","author":"S Coutre","year":"2018","unstructured":"Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA et al (2018) Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood 131(15):1704\u20131711","journal-title":"Blood"},{"issue":"1","key":"5676_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD et al (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19(1):65\u201375","journal-title":"Lancet Oncol"},{"issue":"23","key":"5676_CR37","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M et al (2019) Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380(23):2225\u20132236","journal-title":"N Engl J Med"},{"issue":"4","key":"5676_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C et al (2019) Fixed duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic lymphocytic leukemia eradicates minimal residual disease and prolongs Survival: Post-treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol 37(4):269\u2013277","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"5676_CR39","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1200\/JCO.2023.41.16_suppl.7044","volume":"41","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Donoso LH, Hodzic S, Owusu HF, Pathak D, Zhou SQ et al (2023) Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA). J Clin Oncol 41(16suppl):7044","journal-title":"J Clin Oncol"},{"issue":"9","key":"5676_CR40","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS et al (2018) Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103(9):1511\u20131517","journal-title":"Haematologica"},{"key":"5676_CR41","unstructured":"Metabolically, Optimized Non-cytotoxic Low Dose Weekly Decitabine\/\u200bVenetoclax in MDS and AML clinicaltrials.gov: National Library of Medicine; [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05184842"},{"key":"5676_CR42","unstructured":"Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl, Explorative AML Profiling (LD-VenEx) ClinicalTrials.gov: National Library of Medicine [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05431257"},{"issue":"7","key":"5676_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/M13-0480","volume":"160","author":"DM Hartung","year":"2014","unstructured":"Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M (2014) Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med 160(7):477\u2013483","journal-title":"Ann Intern Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05676-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05676-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05676-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:05:31Z","timestamp":1722060331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05676-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5676"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05676-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests to disclose related to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}